Search results
GenFleet Receives IND Approval from China's NMPA for GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor,...
Tehachapi News· 3 days agoG12D mutation is the most prevalent KRAS mutation detected in human cancers, and no G12D-targeted therapies have been approved yet.
'Knowledge is power' - Message of hope shared in cancer journey - Salisbury Post
The Salisbury Post· 4 days agoWhen Mary Willis Page heard the diagnosis of cancer, she was shocked. While she wasn’t expecting to...